KIR3DL1 and neuroblastoma: Similar to the trends for improved EFS observed in neuroblastoma patients treated with immunotherapy (Figure 1C), those FL patients who were not KIR3DL1+/B-Bw4-I80+ had improved duration of response if treated with maintenance rituximab as compared to no-maintenance (p = 0.002; Figure 2C) (Table S1 in Supplementary Material).